Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BEC2 Vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | NO_INTERVENTION | Best supportive care, but no cancer specific therapy (cytotoxic, radiation or other tumor reductive therapy) can be given until documented progression of disease. |
| 2 | EXPERIMENTAL | Treatment will consist of 5 vaccinations (each consisting of 8 single intradermal injections) over a period of 10 to 12 weeks unless one of the following occur: 1. intolerable toxicity precluding further treatment progression of disease 2. patient refusal 3. occurrence of pregnancy |
| Name | Type | Description |
|---|---|---|
| BEC2 Vaccine | BIOLOGICAL | 5 vaccinations of BEC2 (2.5 mg) + BCG given day 1 of weeks 0,2,4,6 \& 10. |
Inclusion Criteria: * Histo-cytologically proven SCLC * Limited disease at diagnosis * Age greater than or equal to 18 * Patients with a clinical response of CR or PR to first line combined modality therapy * KPS greater than or equal to 60 * Adequate bone marrow, liver and heart functions * Writte...
BEC2 Vaccine is an investigational monoclonal antibody being studied for the treatment of small cell lung cancer, specifically in patients with limited disease. It is administered as an adjuvant vaccine in combination with BCG. The drug is not approved and remains in clinical development.
BEC2 Vaccine is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker symbol LLY. The company is conducting clinical research on this investigational therapy for small cell lung cancer.
BEC2 Vaccine is in Phase 3 clinical development. It has completed a Phase 3 trial in patients with limited disease small cell lung cancer. As an investigational drug, it is not yet approved by regulatory authorities and remains under study.
BEC2 Vaccine has one completed Phase 3 clinical trial, NCT00037713, titled "Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG." The trial enrolled 515 participants and was not double-blinded.
BEC2 Vaccine is also known as BEC2. It is a monoclonal antibody being investigated as an adjuvant vaccine for small cell lung cancer. No other alternative names have been reported for this investigational drug.